Monitor for any future conversion of this 13G to a 13D, which would signal activist intent. The large warrant overhang (17.7M shares) could create dilution risk if exercised, but the blocker limits near-term ownership.
EQ drugs
EQ drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 17 $1.21entry
- T+1 · 4d ago −9.09%α −8.79% · $1.10
- T+3 · todayOpen
- T+5 · tomorrow Pending
- T+20 · in 24d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
RA Capital Management disclosed a 9.9% passive stake in Equillium as of September 30, 2026, up from 4.1% in the prior filing three days earlier. The increase is driven by pre-funded warrants exercisable for up to 17.7 million shares, with a beneficial ownership blocker capping the stake at 9.9%. This is a routine passive update with no change in investment intent.
Key Financial Metrics
Key Facts
- RA Capital Management disclosed a 9.9% passive beneficial ownership stake in Equillium as of September 30, 2026.
- The stake comprises 2,317,741 common shares and pre-funded warrants exercisable for 17,698,593 shares, but a blocker limits total beneficial ownership to 6,712,479 shares (9.9%).
- This is an amendment to a prior Schedule 13G; the prior filing (Nov. 13, 2026) showed a 4.1% stake.
- The filing is passive under Rule 13d-1(c) with no intent to change or influence control.
- The issuer's outstanding shares were 63,408,082 as of August 7, 2026.
Financial Impact
Stake value not disclosed; 9.9% of Equillium's market cap based on 63.4M shares outstanding.
Risk Factors
- Pre-funded warrants represent potential dilution of ~28% of current shares outstanding if fully exercised, though the blocker prevents ownership exceeding 9.9%.
- Passive filing does not preclude future activist activity; a 13D conversion would be a material escalation.
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G/A Filing (Primary) | 0001346824-26-000279 |
| Document: 0001346824-26-000279-index.html | 0001346824-26-000279 |
| Document: 0001346824-26-000279.txt | 0001346824-26-000279 |
Track record
20 reports on EQ
2 of 3 bullish or bearish reports moved the stock their way by T+1. Best: +20.40% at T+60 after the Jun 5, 2026 report. 2 of 3 went positive at some point.
Filters
- Nov 20, 20262d ago EFFECT Neutral 4/10 Entry $1.12 Now $1.06 −5.36% settles Nov 23
- Nov 16, 20265d ago SC 13G/A Neutral 3/10 Viewing Entry $1.21 to $1.10 Now $1.06 −12.40% ▼ −9.09% −8.79% vs SPY
- Nov 13, 20268d ago SC 13G/A Neutral 2/10 Entry $1.15 to $1.21 Now $1.06 −7.83% ▲ +5.22% +6.23% vs SPY
- Nov 12, 20269d ago S-3 Neutral 4/10 Entry $1.29 to $1.15 Now $1.06 −17.83% ▼ −10.85% −8.94% vs SPY
- Nov 12, 20269d ago 8-K Neutral 5/10 Entry $1.29 to $1.15 Now $1.06 −17.83% ▼ −10.85% −8.94% vs SPY
- Nov 12, 20269d ago SC 13G/A Neutral 2/10 Entry $1.32 to $1.29 Now $1.06 −19.70% ▼ −2.27% −1.91% vs SPY
- Nov 4, 202617d ago SC 13G/A Neutral 2/10 Entry $1.40 to $1.33 Now $1.06 −24.29% ▼ −5.00% −0.59% vs SPY
- Oct 26, 202626d ago 8-K Bearish 6/10 Entry $1.36 to $1.42 Now $1.06 +22.06% ▼ −4.41% −4.07% vs SPY
- Oct 26, 202626d ago Press Release Neutral 4/10 Entry $1.25 to $1.36 Now $1.06 −15.20% ▲ +8.80% +8.24% vs SPY
- Oct 5, 20266w ago 8-K Neutral 3/10 Entry $1.42 to $1.39 Now $1.06 −25.35% ▼ −2.11% −1.87% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers